ADXN

Addex Therapeutics

7.63 USD
-0.27
3.42%
At close Dec 23, 4:00 PM EST
1 day
-3.42%
5 days
-5.80%
1 month
-4.03%
3 months
-28.02%
6 months
-0.91%
Year to date
21.11%
1 year
38.48%
5 years
-97.37%
10 years
-97.37%
 

About: Addex Therapeutics Ltd is a clinical stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment which is the discovery, development and commercialization of small-molecule pharmaceutical products.

Employees: 23

0
Funds holding %
of 6,809 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

50% more funds holding

Funds holding: 2 [Q2] → 3 (+1) [Q3]

0% less ownership

Funds ownership: 0% [Q2] → 0% (-0%) [Q3]

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

58% less capital invested

Capital invested by funds: $32.1K [Q2] → $13.6K (-$18.5K) [Q3]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$30
293%
upside
Avg. target
$30
293%
upside
High target
$30
293%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Raghuram Selvaraju
37% 1-year accuracy
117 / 313 met price target
293%upside
$30
Buy
Reiterated
2 Oct 2024

Financial journalist opinion

Neutral
Seeking Alpha
1 month ago
Addex Therapeutics Ltd (ADXN) Q3 2024 Earnings Call Transcript
Addex Therapeutics Ltd (NASDAQ:ADXN ) Q3 2024 Earnings Conference Call November 22, 2024 10:00 AM ET Company Participants Tim Dyer - Co-Founder, Board Director and Chief Executive Officer Mikhail Kalinichev - Head, Translational Science Conference Call Participants Operator Good day, and thank you for standing by. Welcome to the Addex Therapeutics Third Quarter 2024 Financial Results and Corporate Update Conference Call.
Addex Therapeutics Ltd (ADXN) Q3 2024 Earnings Call Transcript
Neutral
GlobeNewsWire
1 month ago
Addex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Indivior selected GABA B PAM drug candidate for development in substance use disorders (SUD) and starts IND enabling studies Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 22, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its third quarter financial results for the periods ended September 30, 2024, and provided a corporate update.
Addex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Negative
Zacks Investment Research
1 month ago
Are Medical Stocks Lagging Addex Therapeutics (ADXN) This Year?
Here is how Addex Therapeutics Ltd. Sponsored ADR (ADXN) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Addex Therapeutics (ADXN) This Year?
Neutral
GlobeNewsWire
1 month ago
Addex Provisional 2024 Third Quarter Results Showed Net Loss Compared to Second Quarter 2024
Nine-month Results Remain On Track for Net Profit Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 11, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its provisional third quarter net results decreased significantly compared to the second quarter 2024.
Addex Provisional 2024 Third Quarter Results Showed Net Loss Compared to Second Quarter 2024
Positive
Zacks Investment Research
2 months ago
What Makes Addex Therapeutics (ADXN) a New Buy Stock
Addex Therapeutics (ADXN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
What Makes Addex Therapeutics (ADXN) a New Buy Stock
Neutral
Seeking Alpha
2 months ago
Addex Therapeutics Ltd (ADXN) Q2 2024 Earnings Call Transcript
Addex Therapeutics Ltd (NASDAQ:ADXN ) Q2 2024 Earnings Conference Call September 30, 2024 10:00 AM ET Company Participants Tim Dyer - Co-Founder, Board Director and Chief Executive Officer Misha Kalinichev - Head, Translational Science Conference Call Participants Raghuram Selvaraju - H.C. Wainwright & Co. Operator Good day, and thank you for standing by.
Addex Therapeutics Ltd (ADXN) Q2 2024 Earnings Call Transcript
Neutral
GlobeNewsWire
2 months ago
Addex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results and Provides Corporate Update
Launched Neurosterix with Perceptive Advisors to accelerate the development of M4PAM for schizophrenia Indivior selected GABA B PAM drug candidate for development in substance use disorders Addex selected independent GABAB PAM drug candidate for development in chronic cough Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 30, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its half-year and second quarter financial results for the periods ended June 30, 2024, and provided a corporate update.
Addex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results and Provides Corporate Update
Neutral
GlobeNewsWire
3 months ago
Addex Provisional 2024 Half-Year and Second Quarter Result increased from a Net loss to a Net Profit
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 19, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its provisional half-year and second quarter net results have increased significantly in 2024 compared to 2023 and first quarter 2024 results primarily due to the sale of part of its business to Neurosterix Pharma Sàrl on April 2, 2024.
Addex Provisional 2024 Half-Year and Second Quarter Result increased from a Net loss to a Net Profit
Negative
Zacks Investment Research
3 months ago
Are Medical Stocks Lagging Addex Therapeutics (ADXN) This Year?
Here is how Addex Therapeutics Ltd. Sponsored ADR (ADXN) and Boston Scientific (BSX) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Addex Therapeutics (ADXN) This Year?
Neutral
GlobeNewsWire
3 months ago
Addex to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Geneva, Switzerland, September 4, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that CEO, Tim Dyer, will be attending the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9 – 11, 2024, at the Lotte New York Palace Hotel.
Addex to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Charts implemented using Lightweight Charts™